For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

Ambulatory acute kidney injury is common among individuals with cirrhosis and is associated with a high 90-day mortality.

For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis.

Sociodemographic disparities, such as low income and lack of health insurance, contribute to reduced CRC screening at age 45 years.

Early-life factors are associated with body mass index trajectories in children, with risk for obesity detectable at age 3.5 years.

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Experienced weight stigma improves from pre- to post-metabolic bariatric surgery, according to a recent study.

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Growth hormone was not associated with a lower risk for the composite liver outcome among patients with adult-onset craniopharyngioma.

More than one-third of patients with SSc screened positive for self-reported depression, with GI involvement identified as the most significant predictor.

Waist-to-height ratio had a better predictive value than BMI in assessing liver fibrosis and steatosis outcomes across ages and racial groups.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.